Acrivon Therapeutics Inc
(ACRV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -35,284 | -16,486 | -60,388 | -41,136 | -26,670 |
| Depreciation Amortization | -1,224 | -353 | -2,787 | -2,256 | -1,647 |
| Accounts payable and accrued liabilities | -3,215 | -2,272 | 3,609 | 439 | 363 |
| Other Working Capital | -1,841 | -3,812 | 8,138 | 3,973 | 2,130 |
| Other Operating Activity | 10,578 | 5,840 | 8,787 | 8,705 | 5,355 |
| Operating Cash Flow | $-30,986 | $-17,083 | $-42,641 | $-30,275 | $-20,469 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -81,242 | 6,665 | 52,005 | 30,318 | 28,802 |
| PPE Investments | -952 | -815 | -1,288 | -137 | -137 |
| Investing Cash Flow | $-82,194 | $5,850 | $50,717 | $30,181 | $28,665 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 70,087 | 79 | 775 | 457 | 379 |
| Other Financing Activity | 53,091 | -251 | -2,329 | 0 | 0 |
| Financing Cash Flow | $123,178 | $-172 | $-1,554 | $457 | $379 |
| Beginning Cash Position | 36,429 | 36,429 | 29,907 | 29,907 | 29,907 |
| End Cash Position | 46,427 | 25,024 | 36,429 | 30,270 | 38,482 |
| Net Cash Flow | $9,998 | $-11,405 | $6,522 | $363 | $8,575 |
| Free Cash Flow | |||||
| Operating Cash Flow | -30,986 | -17,083 | -42,641 | -30,275 | -20,469 |
| Capital Expenditure | -952 | -815 | -1,288 | -137 | -137 |
| Free Cash Flow | -31,938 | -17,898 | -43,929 | -30,412 | -20,606 |